Top ASX healthcare shares with growth potential

While the healthcare sector underperformed in 2025, these three ASX healthcare stocks bucked the trend due to their tremendous potential backed by disciplined execution and favourable tailwinds.

Neuren Pharmaceuticals Limited (ASX: NEU)

surged 49% in 2025 and continues to stand out as a reliable healthcare growth company as global commercialisation of DAYBUE expands and the late-stage neurological pipeline continues to progress.

The company currently has a market capitalisation of $2.50 billion and Q3 2025 DAYBUE (trofinetide) net sales reached US$101.1 million which was up 11% from Q3 2024 and up 5% from Q2 2025.

Neuren is developing multiple drug therapies which target serious neurological disorders that emerge in early childhood and currently have limited or no approved treatment options.
All programs have received orphan drug designation in the United States and the company recorded Q3 2025 royalty income of $16.4 million which increased 24% from Q3 2024 and 12% from Q2 2025.

Acadia reiterated full year DAYBUE U.S. net sales guidance of US$385 to US$400 million which is expected to translate into annual royalties of $63 to $66 million for Neuren.

Sigma Healthcare Limited (ASX: SIG) 

rose 12% in 2025 and went through a transformational year after completing its merger with Chemist Warehouse Group in February 2025 which resulted in the creation of Australia’s largest retail pharmacy franchisor and full line pharmaceutical wholesaler.

The company currently has a market capitalisation of $33 billion and the merger combined Sigma’s wholesale and logistics capabilities with Chemist Warehouse’s strong retail execution.
Sigma now operates a national wholesale and distribution network delivering more than 532 million units annually across 14 distribution centres while continuing to grow its own and exclusive label product range.

Sales from own and exclusive label products increased by more than 20% which supports margin expansion and strengthens the profitability profile of the combined business.

FY25 financial performance reflected this major step up in scale as statutory revenue rose to $6.0 billion representing growth of 80% year-on-year and the company also secured a $1.5 billion syndicated debt facility maturing in 2028 which provides substantial financial flexibility to support integration, working capital requirements and future growth initiatives.

Clinuvel Pharmaceuticals Limited (ASX: CUV)

surged around 3.5% in 2025 and has built momentum in 2026 with a 4% gain over the past week.
On 12 January 2026, the company announced the commencement of dosing in a preclinical study evaluating its in-house developed VLRX-L controlled-release injectable peptide platform with initial results expected in the second half of 2026.

A key milestone in FY25 was progress in the vitiligo Phase III program as the first Phase III trial (CUV105) completed recruitment in May 2025, with early case data presented at major dermatology conferences showing strong repigmentation outcomes in patients with darker skin types.

Revenue increased 8% to $95.0 million while net profit after tax rose 2% to $36.17 million and cash reserves grew 22% to $224.1 million which marked the ninth consecutive year of profitability.
Clinuvel has a debt-free balance sheet which provides flexibility as the company expands its U.S treatment network and moves towards key regulatory milestones.

(Source: Company Reports)